文献速递核素与放射性配体治疗

美国食品药品监督管理局批准后177Lu-PSMA-617放射性配体治疗的真实世界经验

Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
PubMed 文献 · J Nucl Med · 2024-05-01

该研究回顾性分析了99例接受177Lu-PSMA-617放射性配体治疗的患者,评估治疗前PSMA PET、实验室检查、总生存、前列腺特异性抗原下降50%(PSA50)及毒性。60例患者达到PSA50;未符合TheraP PSMA影像标准的18例中7例(39%)达到PSA50,未符合VISION实验室标准的31例中19例(61%)达到PSA50。最常见毒性为贫血(33%)和血小板减少(21%)。

要点

  • 99例患者中60例达到PSA50;未符合TheraP影像标准者18例中7例(39%)达到PSA50。
  • 未符合VISION实验室标准者31例中19例(61%)达到PSA50。
  • 最常见毒性为贫血(33%)和血小板减少(21%)。

核心结论

  • 在本中心,未符合TheraP PSMA影像标准或VISION实验室标准的患者从177Lu-PSMA-617放射性配体治疗中获益。

研究设计与样本

  • 对接受177Lu-PSMA-617治疗的患者进行回顾性分析,评估治疗前PSMA PET、实验室检查、总生存、PSA50及毒性。

主要发现

  • 99例患者纳入分析,其中60例达到PSA50。
  • 未符合TheraP PSMA影像标准的18例患者中7例(39%)达到PSA50。
  • 未符合VISION实验室标准的31例患者中19例(61%)达到PSA50。
  • 63例患者治疗延迟或停止,其中19例因反应良好,14例因疾病进展。
  • 10例反应良好并重新开始治疗的患者中,9例在再治疗时达到PSA50。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report our initial real-world experience with 177Lu-PSMA-617 radioligand therapy. Methods: We performed a retrospective review of patients treated with 177Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated. Results: Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50. Sixty-three patients had a delay or stoppage in therapy, which was due to a good response in 19 patients and progressive disease in 14 patients. Of 10 patients with a good response who restarted treatment, 9 subsequently achieved a PSA50 on retreatment. The most common toxicities were anemia (33%) and thrombocytopenia (21%). Conclusion: At our center, patients who did not meet the TheraP PSMA imaging criteria or the VISION laboratory criteria benefited from 177Lu-PSMA-617 radioligand therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Moradi Tuchayi A, Yadav S, Jiang F, et al. Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. J Nucl Med. 2024. PMID: 38485274. doi:10.2967/jnumed.123.266842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。